NanoViricides Inc., a development stage company focused on creating special purpose nanomaterials for viral therapy, today announced its consulting agreement with Biologics Consulting Group Inc. (BCG), in which the two companies will prepare for submission of Investigational New Drug (IND) applications to the U.S. FDA for NanoViricides’ nanoviricides® drug candidates.

BCG is an international consulting firm providing national and international regulatory and product development assistance for the development and commercial production of drug, biological and device products.

NanoViricides noted the advances and efforts it has made to get its anti-influenza drug candidates to the pre-IND and IND stages. From here on out, the company has engaged BCG to facilitate the FDA review and approval process, as well as to advise the company on the pre-IND application and development activities to follow.

NanoViricides previously reported success in its FluCide™ drug candidates in pre-clinical animal studies, and the company says it remains on track to develop FluCide®.

For more information visit